Search results for "Envelope"

showing 10 items of 336 documents

A Bimolecular Multicellular Complementation System for the Detection of Syncytium Formation: A New Methodology for the Identification of Nipah Virus …

2019

Fusion of viral and cellular membranes is a key step during the viral life cycle. Enveloped viruses trigger this process by means of specialized viral proteins expressed on their surface, the so-called viral fusion proteins. There are multiple assays to analyze the viral entry including those that focus on the cell-cell fusion induced by some viral proteins. These methods often rely on the identification of multinucleated cells (syncytium) as a result of cell membrane fusions. In this manuscript, we describe a novel methodology for the study of cell-cell fusion. Our approach, named Bimolecular Multicellular Complementation (BiMuC), provides an adjustable platform to qualitatively and quanti…

0301 basic medicinevirusesmembrane fusionlcsh:QR1-502virusNipah virusBiologyGiant Cells01 natural scienceslcsh:MicrobiologySmall Molecule Libraries03 medical and health sciencesVirus entryViral envelopeViral life cycleViral entryVirologyDrug DiscoveryHumansSyncytiumDrug discoveryBrief ReportbiomolèculesHigh-throughput screeningLipid bilayer fusionVirus InternalizationFusion proteinHigh-Throughput Screening Assays0104 chemical sciencesCell biologyBimolecular complementation010404 medicinal & biomolecular chemistryMulticellular organismHEK293 Cells030104 developmental biologyInfectious DiseasesViruses
researchProduct

T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice.

2013

Background & Aims Antiviral agents suppress hepatitis B virus (HBV) replication but do not clear the infection. A strong effector T-cell response is required to eradicate HBV, but this does not occur in patients with chronic infection. T cells might be directed toward virus-infected cells by expressing HBV-specific receptors and thereby clear HBV and help to prevent development of liver cancer. In mice, we studied whether redirected T cells can engraft after adoptive transfer, without prior T-cell depletion, and whether the large amounts of circulating viral antigens inactivate the transferred T cells or lead to uncontrolled immune-mediated damage. Methods CD8 + T cells were isolated from m…

Adoptive cell transferHepatitis B virusRecombinant Fusion ProteinsReceptors Antigen T-CellMice TransgenicAdoptive T-Cell TherapyCD8-Positive T-Lymphocytesmedicine.disease_causeVirus ReplicationInterleukin 21MiceViral Envelope ProteinsmedicineCytotoxic T cellAnimalsHumansIL-2 receptorAntigen-presenting cellHepatitis B virusCD40HepatologybiologyZAP70Gastroenterologyvirus diseasesHepatocellular CarcinomaVirologyMolecular biologyAdoptive TransferMice Inbred C57BLLiverbiology.proteinImmunotherapyChronic Hepatitis BGastroenterology
researchProduct

Stable changes in CD4+ T lymphocyte miRNA expression after exposure to HIV-1

2012

Abstract MicroRNAs (miRNAs) inhibit HIV-1 expression by either modulating host innate immunity or by directly interfering with viral mRNAs. We evaluated the expression of 377 miRNAs in CD4+ T cells from HIV-1 élite long-term nonprogressors (éLTNPs), naive patients, and multiply exposed uninfected (MEU) patients, and we observed that the éLTNP patients clustered with naive patients, whereas all MEU subjects grouped together. The discriminatory power of miRNAs showed that 21 miRNAs significantly differentiated éLTNP from MEU patients and 23 miRNAs distinguished naive from MEU patients, whereas only 1 miRNA (miR-155) discriminated éLTNP from naive patients. We proposed that miRNA expression ma…

AdultCD4-Positive T-LymphocytesMaleTime FactorsImmunologyHIV InfectionsHIV Envelope Protein gp120BiologyBiochemistryImmune systemmultiply exposed uninfectedmicroRNAHumansDroshamiRNAInnate immune systemélite long-term nonprogressorsGene Expression ProfilingCell BiologyHematologyT lymphocyteMiddle AgedViral LoadMicroarray AnalysisHIV-1; miRNA; CD4+ T cells; élite long-term nonprogressors; multiply exposed uninfected.CD4+ T cellsIn vitroMicroRNAsGene Expression RegulationCase-Control StudiesImmunologyHIV-1biology.proteinFemaleEx vivoDicerBlood
researchProduct

Free and antibody-complexed antigen and antibody profile in apparently healthy HIV seropositive individuals and in AIDS patients.

1990

The pattern of free and antibody-complexed HIV antigen and the antibody profile were investigated retrospectively in 305 serum samples taken from 22 AIDS patients before and during the development of AIDS and from 40 apparently healthy seropositive individuals. Most AIDS patients were found positive for both free and complexed antigen and had high gp41 antibody titres but low or undetectable p24 antibody. Four different patterns of HIV antigenaemia were observed: 1) positive for both free and complexed antigen; 2) negative for free HIV antigen at first, but always positive for complexed antigen; 3) positive for free antigen without complexed antigen; and 4) negative for both free and comple…

AdultMaleAntigen-Antibody ComplexHIV AntigensHIV Core Protein p24Gene Products gagAntigen-Antibody ComplexBiologyHIV AntibodiesVirusImmune systemAcquired immunodeficiency syndrome (AIDS)AntigenHIV SeroprevalenceVirologyHIV SeropositivitymedicineHumansSubstance Abuse IntravenousAcquired Immunodeficiency SyndromeViral Core Proteinsmedicine.diseaseVirologyImmune complexHIV Envelope Protein gp41Infectious DiseasesItalyImmunologybiology.proteinFemaleViral diseaseAntibodyBiomarkersJournal of medical virology
researchProduct

Effect of antiviral treatment and host susceptibility on positive selection in hepatitis C virus (HCV).

2007

Abstract We have conducted a large sequence study of the E1–E2 and NS5A regions of the HCV, subtypes 1a and b, both in patients previously treated with interferon, and untreated patients, who later responded, or not, to a combination therapy based on interferon plus ribavirin. We have examined the role played by the number of positively selected sites on disease progression and its relationship with several variables such as patients’ age, sex and their risk of acquiring the disease. We have detected three groups of patients that respond or not to combination therapy: responders of intermediate age, older non-responders and young non-responders, they possess an increasing average number of …

AdultMaleCancer ResearchCombination therapyHepatitis C virusMolecular Sequence DataDiseaseHepacivirusBiologyViral Nonstructural Proteinsmedicine.disease_causeAntiviral Agentschemistry.chemical_compoundViral Envelope ProteinsInterferonVirologyRibavirinmedicineHumansAmino Acid SequenceSelection GeneticNS5AAgedHost (biology)Positive selectionRibavirinSequence Analysis DNAMiddle AgedHepatitis CInfectious DiseasesTreatment OutcomechemistryAmino Acid SubstitutionImmunologyRNA ViralFemaleInterferonsmedicine.drugVirus research
researchProduct

Immune blot analysis of viral surface proteins in serum and liver of patients with chronic hepatitis B virus infection

1989

The small and the middle surface proteins of hepatitis virus form either the virion or the 22 nm particle both of which are secreted. The large surface protein by itself remains cell bound in artificially transfected cell culture unless it is accompanied by an excess of the smaller protens. Its behavior in vivo is not yet well studied. Using specific monoclonal antibodies for immunoblotting, we found an abundance of small surface protein in the serum of chronic virus carriers and moderate amounts in the liver irrespective of viremia. The large surface protein was present in the serum and the liver of viremic carriers. In nonviremic carriers, the large protein was absent from serum, but in t…

AdultMaleHepatitis B virusmedicine.drug_classvirusesImmunoblottingBiologyMonoclonal antibodymedicine.disease_causeVirus03 medical and health sciences0302 clinical medicineViral envelopeVirologymedicineHumansAgedHepatitis Chronic030304 developmental biologyHepatitis B virusHepatitis0303 health sciencesHepatitis B Surface AntigensMiddle AgedHepatitis Bbiology.organism_classificationmedicine.diseaseVirologyMolecular biology3. Good healthBlotBloodInfectious DiseasesLiverHepadnaviridaeCell cultureFemale030211 gastroenterology & hepatologyJournal of Medical Virology
researchProduct

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical tr…

2019

BACKGROUND: The adjuvanted recombinant zoster vaccine (Shingrix) can prevent herpes zoster in older adults and autologous haemopoietic stem cell transplant recipients. We evaluated the safety and immunogenicity of this vaccine in adults with haematological malignancies receiving immunosuppressive cancer treatments. METHODS: In this phase 3, randomised, observer-blind, placebo-controlled study, done at 77 centres worldwide, we randomly assigned (1:1) patients with haematological malignancies aged 18 years and older to receive two doses of the adjuvanted recombinant zoster vaccine or placebo 1-2 months apart during or after immunosuppressive cancer treatments, and stratified participants acco…

AdultMaleHerpesvirus 3 Humanmedicine.medical_specialtyAdolescentPopulationAntineoplastic AgentsAntibodies ViralPlaceboHematological malignanciesImmunocompromised HostYoung Adult03 medical and health sciences0302 clinical medicineViral Envelope ProteinsInternal medicinemedicineHerpes Zoster VaccineHumansSingle-Blind Method030212 general & internal medicineeducationAdverse effectFatigueImmunity CellularVaccines Syntheticeducation.field_of_studyVaccinesReactogenicityH. Zosterbusiness.industryImmunogenicityMiddle AgedCD4 Lymphocyte CountInjection Site ReactionVaccinationClinical trialInfectious DiseasesHematologic Neoplasms030220 oncology & carcinogenesisH. Zoster; Vaccines; Hematological malignanciesFemaleZoster vaccinebusinessVaccinemedicine.drug
researchProduct

Early neutralizing and glycoprotein B (gB)-specific antibody responses to human cytomegalovirus (HCMV) in immunocompetent individuals with distinct c…

2000

Abstract Background: Antibodies with functional anti-Human Cytomegalovirus (HCMV) activity are likely to be involved in preventing virus dissemination and thus may contribute to minimize the clinical manifestations of infection. Objectives: To investigate the role of humoral immunity in modulating the clinical expression of primary Human Cytomegalovirus (HCMV) infection in immunocompetent persons. Study design: Neutralizing (NA) and glycoprotein B (gB)-specific antibodies were quantitated in acute-phase and late-convalescence phase sera from 19 individuals who developed either HCMV mononucleosis (12) or oligosymptomatic hepatitis (seven). Results: The levels of NA in sera drawn early after …

AdultMaleHuman cytomegalovirusAdolescentHepatitis Viral HumanMononucleosisvirusesAntibody AffinityCongenital cytomegalovirus infectionBiologyAntibodies ViralViral Envelope ProteinsNeutralization TestsVirologymedicineHumansAvidityInfectious MononucleosisChildmedicine.diseaseVirologyInfectious DiseasesChild PreschoolImmunoglobulin GCytomegalovirus InfectionsDNA ViralHumoral immunityImmunologybiology.proteinFemaleAntibodyViral hepatitisImmunocompetenceViral loadJournal of Clinical Virology
researchProduct

Antibody response to human cytomegalovirus (HCMV) glycoprotein B (gB) in AIDS patients with HCMV end-organ disease

1998

Human cytomegalovirus (HCMV)-specific antibody responses in HIV-1 infected individuals either with or without HCMV end-organ disease were examined to determine the whether development of HCMV disease was associated with a particular deficit in the antibody response. Antiwhole HCMV, anti-glycoprotein B (gB), and neutralizing antibody levels were higher in HIV-1 infected individuals than in healthy immunocompetent subjects, particularly in patients with AIDS either with or without HCMV-associated disease. Irrespective of location and spread of HCMV disease, patients who had received anti-HCMV therapy prior to sampling exhibited significantly higher anti-gB and neutralizing antibody titers tha…

AdultMaleHuman cytomegalovirusAdolescentvirusesCytomegalovirusBiologyAntibodies ViralAntiviral AgentsViral Envelope ProteinsNeutralization TestsBetaherpesvirinaeVirologyImmunopathologymedicineHumansViremiaFluorescent Antibody Technique IndirectNeutralizing antibodyAcquired Immunodeficiency SyndromeAIDS-Related Opportunistic InfectionsAntibody titervirus diseasesbiochemical phenomena metabolism and nutritionmedicine.diseasebiology.organism_classificationVirologyCD4 Lymphocyte CountInfectious DiseasesImmunoglobulin GCytomegalovirus InfectionsImmunologyHIV-1biology.proteinFemaleViral diseaseAntibodyViral loadJournal of Medical Virology
researchProduct

CD4-mediated regulatory T-cell activation inhibits the development of disease in a humanized mouse model of allergic airway disease

2012

Background Based on their potency to control allergic diseases, regulatory T (Treg) cells represent a promising target for novel strategies to interfere with allergic airway inflammation. We have previously demonstrated that stimulation of the CD4 molecule on human Treg cells activates their suppressive activity in vitro and in vivo . Objective We sought to determine the effect of CD4-mediated Treg-cell activation on pulmonary inflammation in a humanized mouse model of allergic airway inflammation. Methods PBMCs obtained from donors allergic to birch pollen or from healthy donors were injected into NOD-severe combined immunodeficiency γc −/− mice, followed by allergen airway challenges and …

AdultMaleRegulatory T cellAHRImmunologychemical and pharmacologic phenomenaInflammationMice SCIDHIV Envelope Protein gp120pulmonary inflammationmedicine.disease_causeT-Lymphocytes Regulatoryregulatory T cellsMiceImmune systemAllergenRespiratory HypersensitivitymedicineAnimalsHumansImmunology and AllergyImmunodeficiencySensitizationSevere combined immunodeficiencybusiness.industryhemic and immune systemsPneumoniaMiddle Agedrespiratory systemmedicine.diseaseRecombinant ProteinsHumanized animal modelrespiratory tract diseasesDisease Models Animalmedicine.anatomical_structureCD4 AntigensImmunologyHumanized mouseLeukocytes MononuclearFemaleInterleukin-4Bronchial Hyperreactivitymedicine.symptombusinessJournal of Allergy and Clinical Immunology
researchProduct